A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(20 sites)

Australia

GenesisCare North Shore, Sydney, New South Wales

Westmead Hospital, Westmead, New South Wales

ICON Cancer Centre South Brisbane, Brisbane, Queensland

Greenslopes Private Hospital, Greenslopes, Queensland

Southern Oncology Clinical Research Unit, Adelaide, South Australia